Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

APRIL WANG ARMSTRONG

Allopathic & Osteopathic Physicians Dermatology

NPI
1356477087
CMS profile
152935
Location
LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$303,565.78

128 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 128 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

APRIL WANG ARMSTRONG

NPI 1356477087 · CMS profile ID 152935

Allopathic & Osteopathic Physicians / Dermatology

LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 128 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1356477087?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
APRIL WANG ARMSTRONG, NPI 1356477087, CMS profile ID 152935. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 128 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356477087?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). APRIL WANG ARMSTRONG, NPI 1356477087, CMS profile ID 152935. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 128 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356477087?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
APRIL WANG ARMSTRONG, NPI 1356477087, CMS profile ID 152935, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 128 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1356477087?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

128 matching records · $303,565.78 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 128 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 128.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Scientific Affairs, LLC $1,350.0009/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788149213 CMS
E.R. Squibb & Sons, L.L.C. $2,040.0009/03/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783515681 CMS
Janssen Research & Development, LLC $1,240.0008/31/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787614929 CMS
UCB, Inc. $1,600.0008/30/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807472117 CMS
GENZYME CORPORATION $5,992.0008/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843647107 CMS
GENZYME CORPORATION $2,139.0008/12/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843647117 CMS
AbbVie Inc. $15.2008/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793916913 CMS
AbbVie Inc. $2,100.0008/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793916909 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $2,880.0007/31/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814947541 CMS
AbbVie Inc. $2,450.0007/22/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793916901 CMS
AbbVie Inc. $1,400.0007/22/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793916905 CMS
GENZYME CORPORATION $1,426.0007/20/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843647089 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $3,960.0007/17/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814947591 CMS
AbbVie Inc. $700.0007/13/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793916897 CMS
E.R. Squibb & Sons, L.L.C. $5,075.0007/09/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783515669 CMS
UCB, Inc. $2,490.0007/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807471677 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $3,000.0006/30/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851860941 CMS
Eli Lilly and Company $2,625.0006/29/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818952399 CMS
Lilly USA, LLC $3,937.5006/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818949739 CMS
UCB SA $3,320.0006/22/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844947961 CMS
AbbVie Inc. $700.0006/21/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793916889 CMS
AbbVie Inc. $4,550.0006/21/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793916893 CMS
Janssen Biotech, Inc. $38.2306/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788149199 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $1,440.0006/17/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814947569 CMS
UCB SA $1,500.0006/11/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803250119 CMS
AbbVie Inc. $3,500.0006/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793916885 CMS
Boehringer Ingelheim International GmbH $2,750.0006/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 822297695 CMS
E.R. Squibb & Sons, L.L.C. $5,425.0006/04/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783515653 CMS
AbbVie Inc. $700.0006/03/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793916881 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $1,440.0006/03/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814947579 CMS
Incyte Corporation $2,800.0006/02/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835548201 CMS
GENZYME CORPORATION $5,348.0005/28/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843647091 CMS
LEO Pharma Inc. $4,980.0005/28/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842134895 CMS
E.R. Squibb & Sons, L.L.C. $2,040.0005/26/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783515643 CMS
E.R. Squibb & Sons, L.L.C. $2,720.0005/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783515645 CMS
LEO Pharma Inc. $2,490.0005/21/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842134871 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $720.0005/20/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814947555 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $1,440.0005/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814947561 CMS
Novartis Pharmaceuticals Corporation $4,320.0005/18/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812591479 CMS
E.R. Squibb & Sons, L.L.C. $4,500.0005/12/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783515639 CMS
Janssen Research & Development, LLC $1,550.0005/12/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787614825 CMS
GENZYME CORPORATION $3,424.0005/11/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843647055 CMS
Janssen Scientific Affairs, LLC $1,350.0005/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788149211 CMS
Eli Lilly and Company $3,500.0004/30/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818952403 CMS
GENZYME CORPORATION $1,000.0004/30/2021 Grant No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843647023 CMS
Janssen Scientific Affairs, LLC $1,350.0004/24/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788149207 CMS
Janssen Scientific Affairs, LLC $1,350.0004/24/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788149209 CMS
Janssen Scientific Affairs, LLC $1,350.0004/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788149203 CMS
Janssen Global Services, LLC $3,720.0004/14/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787614937 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $45.6004/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814947603 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $200,786.37 186
PY2020 $198,048.92 98
PY2021 $303,565.78 128
PY2022 $320,166.33 219
PY2023 $358,373.30 243
PY2024 $448,351.87 265
PY2025 $520,638.63 339

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $20,381.82 9
PY2025 Principal investigator $835,540.80 42
PY2024 Recipient $39,276.49 18
PY2024 Principal investigator $652,921.74 24
PY2023 Recipient $22,140.00 10
PY2023 Principal investigator $250,134.92 102
PY2022 Recipient $34,074.34 16
PY2022 Principal investigator $308,373.75 64
PY2021 Recipient $33,209.41 31
PY2021 Principal investigator $348,028.53 65
PY2020 Recipient $26,909.25 10
PY2020 Principal investigator $663,687.93 52
PY2019 Recipient $7,150.03 11
PY2019 Principal investigator $744,610.29 92

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

51 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $46,486.00 12/29/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1175442796
Principal investigator 1 Janssen Research & Development, LLC $11,681.00 12/25/2025 Non-covered Recipient Entity
OLIVE VIEW-UCLA EDUCATION & RESEARC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175441985
Recipient Novartis Pharmaceuticals Corporation $2,168.50 12/22/2025 Covered Recipient Physician Research Publication/ Writing Support No dispute reported 06/30/2026 1190291386
Principal investigator 1 Janssen Research & Development, LLC $1,934.00 12/15/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175442684
Recipient Regeneron Pharmaceuticals, Inc. $340.91 12/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184115195
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $23,672.67 12/01/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223268956
Principal investigator 1 Janssen Research & Development, LLC $17,580.00 11/03/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1175442679
Principal investigator 1 Janssen Research & Development, LLC $6,906.00 10/27/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175442982
Principal investigator 1 Janssen Research & Development, LLC $3,588.00 10/24/2025 Non-covered Recipient Entity
OLIVE VIEW-UCLA EDUCATION & RESEARC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175442009
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,137.46 10/21/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223268946
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $19,601.54 10/21/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223268948
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $31,023.58 10/01/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223268944
Principal investigator 1 Janssen Research & Development, LLC $1,868.00 09/29/2025 Non-covered Recipient Entity
OLIVE VIEW-UCLA EDUCATION & RESEARC H INSTITUTE INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175442002
Principal investigator 1 Janssen Research & Development, LLC $37,238.00 09/29/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1175442631
Recipient Amgen Inc. $3,654.03 09/23/2025 Covered Recipient Physician A Phase 4, Multi-center, Randomized, Double-blind, Placebo-controlled Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Subjects With Manifestations of Plaque Psoriasis and Impaired Quality of Life No dispute reported 06/30/2026 1246636956
Principal investigator 1 Amgen Inc. $2,030.55 09/22/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) No dispute reported 06/30/2026 1246638648
Recipient GENZYME CORPORATION $500.00 09/19/2025 Covered Recipient Physician A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Dose Ranging Study of a Subcutaneous Anti-OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226125715
Recipient Novartis Pharma AG $509.29 09/10/2025 Covered Recipient Physician CAIN-AB No dispute reported 06/30/2026 1248109097
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $16,074.45 09/09/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223268940
Principal investigator 1 Janssen Research & Development, LLC $8,267.00 09/08/2025 Non-covered Recipient Entity
OLIVE VIEW-UCLA EDUCATION & RESEARC H INSTITUTE INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175441991
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,503.17 09/02/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223268938
Principal investigator 1 Janssen Research & Development, LLC $2,817.00 09/01/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175442730
Principal investigator 1 Janssen Research & Development, LLC $52,767.00 09/01/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1175442837
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $21,384.09 08/12/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223268934
Recipient Amgen Inc. $3,866.44 08/08/2025 Covered Recipient Physician Early initiation of Apremilast. No dispute reported 06/30/2026 1246636960
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,770.66 08/01/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223268922
Principal investigator 1 Janssen Research & Development, LLC $13,759.00 07/31/2025 Non-covered Recipient Entity
OLIVE VIEW-UCLA EDUCATION & RESEARC H INSTITUTE INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175441997
Principal investigator 1 Janssen Research & Development, LLC $2,817.00 07/28/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175442719
Recipient Boehringer Ingelheim International GmbH $1,925.00 07/24/2025 Covered Recipient Physician BI 655130 Spesolimab - Project Committee(s) No dispute reported 06/30/2026 1220622424
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,563.52 07/17/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223268918
Principal investigator 1 Janssen Research & Development, LLC $2,817.00 06/30/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175442926
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,101.92 06/20/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223281722
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,892.38 06/12/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223281182
Principal investigator 1 Janssen Research & Development, LLC $5,772.00 05/26/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175442580
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,157.68 05/13/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223279408
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,369.48 05/01/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223278798
Principal investigator 1 Janssen Research & Development, LLC $4,794.00 04/28/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175442891
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $18,315.36 04/10/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223277814
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $47,154.00 04/10/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223277818
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,362.88 04/10/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223277826
Principal investigator 1 Janssen Research & Development, LLC $4,321.00 03/24/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175443064
Recipient PFIZER INC. $3,200.00 03/18/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228770245
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,542.86 03/18/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223268912
Principal investigator 1 Janssen Research & Development, LLC $8,516.00 03/03/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175442972
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $20,700.54 02/18/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223268910
Principal investigator 1 Incyte Corporation $2,335.71 01/28/2025 Non-covered Recipient Entity
UCLA
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 1240605088
Principal investigator 1 Janssen Research & Development, LLC $7,564.00 01/27/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175442909
Recipient Amgen Inc. $4,217.65 01/21/2025 Covered Recipient Physician A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Early, Oligoarticular Psoriatic Arthritis Despite Initial Stable Treatment With Either NSAIDS and/or = 1 Conventional Synthetic DMARD No dispute reported 06/30/2026 1246636958
Principal investigator 1 Amgen Inc. $219,469.48 01/21/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246638640
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $18,656.82 01/16/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223268904
Principal investigator 1 Amgen Inc. $41,228.00 01/02/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 3, Open-label, 52-week Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab (AMG 451) in Adolescent Subjects Aged ? 12 to < 18 Years With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Orbit) No dispute reported 06/30/2026 1246638644